Pfizer has received approval for a proposal to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals (Mylan) for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane. The said Marketing and supply agreement will be for a period of 5 years within the territory of India.
Mylan has a good presence in Central Nervous System therapy area with skilled resources for engagement with super specialists namely Neurologist and Psychiatrist. This arrangement with Mylan will enhance distribution and in clinic presence of the products of the company. The Board of Directors of the company at their Meeting held on February 20, 2025 has approved the same.
Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
